Prognostic significance of nuclear pSTAT3 in oral cancer

Head and Neck

Volumn 33, Issue 4, 2011, Pages 482-489

  MacHa, Muzafar A ^a   Matta, Ajay ^a   Kaur, Jatinder ^a   Chauhan, S S ^a   Thakar, Alok ^a   Shukla, Nootan K ^a   Gupta, Siddhartha Datta ^b   Ralhan, Ranju ^c,d  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

dysplasia; leukoplakia; OSCC; pSTAT3; STAT3

Indexed keywords

NUCLEAR PROTEIN; STAT3 PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SQUAMOUS CELL CARCINOMA; TOBACCO;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 79952915071     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21468     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
3. SEER Stat Database: Incidence-SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. 2007. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: http://www.seer.cancer.gov
4. Mithani SK, Mydlarz WK, Grumbine FL, Smith IM, Califano JA,. Molecular genetics of premalignant oral lesions. Oral Dis 2007; 13: 126-133.
5. Warnakulasuriya KA, Ralhan R,. Clinical, pathological, cellular and molecular lesions caused by oral smokeless tobaccoâ€"a review. J Oral Pathol Med. 2007; 36: 63-77. (Pubitemid 46089306)
6. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 2009; 1171: 59-76.
7. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
8. Haura EB, Zheng Z, Song L, Cantor A, Bepler G,. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8288-8294. (Pubitemid 41746939)
9. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000-2008. (Pubitemid 34270888)
10. Schaefer LK, Ren Z, Fuller GN, Schafer TS,. Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 2002; 21: 2058-2065. (Pubitemid 34270894)
11. Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007; 26: 2435-2444. (Pubitemid 46597261)
12. Diaz N, Minton S, Cox C, et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006; 12: 20-28. (Pubitemid 43166171)
13. Sinha P, Bahadur S, Thakar A, et al. Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. Head Neck 2009; 31: 1423-1430.
14. Shah NG, Trivedi TI, Tankshali RA, et al. Stat3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. Int J Biol Markers 2006; 21: 175-183. (Pubitemid 44660290)
15. Shah NG, Trivedi TI, Tankshali RA, et al. Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. Int J Biol Markers 2007; 22: 132-143. (Pubitemid 47062218)
16. Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002; 62: 3351-3355. (Pubitemid 34651376)
17. Shah NG, Trivedi TI, Tankshali RA, et al. Stat3 expression in oral squamous cell carcinoma: association with clinicopathological parameters and survival. Int J Biol Markers 2006; 21: 175-183. (Pubitemid 44660290)
18. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, Gutkind JS,. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 2006; 8: 733-746. (Pubitemid 44465525)
19. Nagpal JK, Mishra R, Das BR,. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 2002; 94: 2393-2400. (Pubitemid 34457120)
20. Klosek SK, Nakashiro K, Hara S, Li C, Shintani S, Hamakawa H,. Constitutive activation of Stat3 correlates with increased expression of the c-Met/HGF receptor in oral squamous cell carcinoma. Oncol Rep 2004; 12: 293-296.
21. Sheen-Chen SM, Huang CC, Tang RP, Chou FF, Eng HL,. Prognostic value of signal transducers and activators of transcription 3 in breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 2286-2290.
22. Cortas T, Eisenberg R, Fu P, Kern J, Patrick L, Dowlati A,. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer 2007; 55: 349-355. (Pubitemid 46343578)
23. Coppola D,. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000; 7: 421-427.
24. Sawhney M, Rohatgi N, Kaur J, et al. Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer 2007; 120: 2545-2556. (Pubitemid 46651274)
25. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999; 98: 295-303. (Pubitemid 29380565)
26. Frank DA,. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007; 251: 199-210. (Pubitemid 46680370)
27. Chen RJ, Ho YS, Guo HR, Wang YJ,. Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci 2008; 104: 283-293.
28. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA,. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK- 2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 2006; 20: 2093-2101. (Pubitemid 44953908)
29. Svetlana A, Tsareva Y, Morigglz R, et al. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction 1. Neoplasia 2007; 279: 279-291.
30. Selvendiran K, Bratasz A, Kuppusamy ML, Tazi MF, Rivera BK, Kuppusamy P,. Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3. Int J Cancer 2009; 125: 2198-2204.
31. Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107: 351-362.
32. Germain D, Frank DA,. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 2007; 13: 5665-5669. (Pubitemid 47583890)
33. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 2003; 100: 4138-4143. (Pubitemid 36418170)
34. Klosek SK, Nakashiro K, Hara S, Goda H, Hamakawa H,. Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma. Oncol Rep 2008; 20: 873-878.
35. Chakravarti N, Myers JN, Aggarwal BB,. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int J Cancer 2006; 119: 1268-1275. (Pubitemid 44258799)
36. Leeman-Neill RJ, Wheeler SE, Singh SV, et al. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009; 30: 1848-1856.
37. Kim ES, Hong SY, Lee HK, et al. Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells. Oncol Rep 2008; 20: 1321-1327.
38. Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal BB,. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 2008; 68: 4406-4415.